CClinicalTrials.gg
TerminatedNCT00059228Updated Jun 13, 2018Results posted

Clinical Trial of Estrogen for Postpartum Depression

A Phase 2 interventional study of 17beta Estradiol and Placebos in Postpartum Depression and Depression, sponsored by National Institute of Mental Health (NIMH). Terminated at 1 site in United States. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by National Institute of Mental Health (NIMH) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

This study evaluates the efficacy of estrogen treatment in women with postpartum depression (PPD).

PPD causes significant distress to a large number of women; the demand for effective therapies to treat PPD is considerable. Estradiol therapy has a prophylactic effect in women at high risk for developing PPD. The prevention of a decline in estradiol levels may prevent the onset of PPD. Studies also suggest that estradiol has antidepressant effects in women and may provide a safe and effective alternative to traditional antidepressants in women with PPD.

Participants will be screened with a medical history, physical examination, blood and urine tests, psychological tests, genetic studies, and self-rating scales and questionnaires. Upon study entry, women will be randomly assigned to wear skin patches containing either estradiol or placebo (a patch with no active ingredient) for 6 weeks. Women who receive estradiol and do not menstruate during the last week of the study will receive progesterone for 7 days to initiate menstruation. Women who receive placebo and do not menstruate during the last week of the study will continue to receive placebo at the end of the study. Every week, participants will have blood taken and will be asked to complete symptom self-rating scales. A urine sample and blood samples will be collected at different time points through out of the study. Participants who receive placebo and those whose symptoms do not improve with estradiol therapy will be offered treatment with standard antidepressant medications for 8 weeks at the end of the study.

Read the detailed description

Postpartum-related mood disorders cause significant distress to a potentially large number of women. The demand for effective therapies for treating these mood disorders is considerable, as is the need to define clinical or biologic markers that may predict successful response of these mood disturbances to estradiol. Despite the prevalence of postpartum depressions, only a few double-blind, controlled trials of antidepressant agents have been performed in this condition (1-4)- only two of which were placebo-controlled. A recent large multicenter trial failed to confirm the initially promising but anecdotal reports of the protective role of fish oil in PPD (5). Similarly, despite evidence of estradiol s therapeutic efficacy in trials

that were both open (monotherapy) (6) and controlled (combined with traditional antidepressant agents (7)), the potential of estradiol to be an effective alternative to traditional psychotropics in postpartum depression has not been examined under controlled conditions.

Postpartum depressions occur by definition after delivery when women are relatively hypogonadal. Indeed, plasma estradiol and progesterone levels are low and comparable to those seen during the peri and postmenopause. However, there is no evidence that postpartum depression represents a simple hormone deficiency, and women with postpartum depression are not distinguished from women without postpartum depression on the basis of any abnormality of basal reproductive hormones. Nonetheless, a role for declining estradiol secretion has been suggested by the following observations: 1) estradiol therapy has been reported to have a prophylactic effect in women at high risk for developing postpartum depression (8), suggesting that the prevention of a decline in estradiol levels (threshold or rate of decline) may prevent the onset of postpartum depression in some women; and (2) declining ovarian steroids trigger the onset of mood disturbances in women with but not women without a history of postpartum depression during a scaled down model of pregnancy in the puerperium (9). Thus, as with depressions occurring during the perimenopause, when ovarian hormone secretion is also declining, postpartum depression may also be responsive to estradiol therapy. In fact, open trials of estradiol therapy in postpartum depression (6) as well as a trial of estradiol in combination with traditional antidepressants (7) have suggested that estradiol does have antidepressant-like effects that are observed within a three week time period in women with postpartum onset major depression. Thus, estradiol treatment may not only provide a safe and effective alternative to traditional antidepressants in women with postpartum depression, but it may also suggest the relevant hormonal trigger for the development of this condition.

In this protocol we wish to investigate the effects of estradiol on mood in women with moderately severe postpartum depression under placebo controlled conditions. This protocol will address the following question: 1) Does estradiol improve mood in postpartum depressed women?

02

Conditions studied

  • Postpartum Depression
  • Depression

Keywords

  • Pregnancy
  • Gonadal Steroids
  • Antidepressants
  • Puerperium
  • Depression
  • Postpartum
  • Estradiol
  • Estrogen Response Element
  • Postpartum Depression
03

In context

Depression, Postpartum

528 studies on the registry are indexed under Depression, Postpartum; 124 are open to participants now.

This study's enrollment of 12 is below the median of 105 across 425 interventional studies indexed under Depression, Postpartum.

Browse Depression, Postpartum studies →

Lead sponsor

National Institute of Mental Health (NIMH) is the lead sponsor of 359 studies on the registry; 46 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. A history of at least two weeks with postpartum-related mood disturbances of moderate severity, and self-report of the onset of depression within three months of a normal vaginal delivery or uncomplicated Caesarean section;

    1. A current episode of minor (meeting 3-4 criterion symptoms) or major depression (of moderate severity or less on the SCID severity scale and not meeting DSM-IV criteria symptom 9 [suicidal ideation]) as determined by the administration of the minor depression module of the SADS-L and the Structured Clinical Interview for DSM-IV. Additionally, to ensure that subjects meet a minimum threshold for severity of depression, subjects will have scores greater than or equal to 10 on either the Beck Depression Inventory (BDI) or the Center for Epidemiologic Studies - Depression (CES-D) Scale during at least three of the six clinic visits during the two week screening phase, as well as a 17 item Hamilton Depression score greater than or equal to 10. Subjects will be excluded if they meet any of the following criteria: major depression of greater than moderate severity (including postpartum psychosis). DSM-IV criteria #9 (suicidal ideation), or anyone requiring immediate treatment after clinical assessment.
    2. Not greater than six months post delivery;
    3. Age 20 to 45;
    4. In good medical health, and not taking any medication or dietary and herbal supplements on a regular basis (with the exception of multivitamins or calcium supplements).

Exclusion criteria

EXCLUSION CRITERIA:

The following conditions will constitute contraindications to treatment and will preclude a subject s participation in this protocol:

  1. severe major depression with any of the following:

    • positive (threshold) response to SCID major depression section item # 9, suicidal ideation;
    • anyone requiring immediate treatment after clinical assessment;
    • severity ratings greater than moderate on the SCID IV interview (including postpartum psychosis);
  2. current treatment with antidepressant medications
  3. history of psychiatric illness during the two years before the reported onset of the current episode of depression or a history of either mania (DSM-IV criteria) or postpartum psychosis at any time in the past.
  4. history of ischemic cardiac disease, pulmonary embolism, retinal thrombosis, or thrombophlebitis; any subject with risk factors for thrombo-embolic phenomena including cigarette smokers (greater than 10 cigarettes per day), varicose veins, patients with prolonged periods of immobilization (including prolonged travel), and active heart disease.
  5. renal disease, asthma
  6. hepatic dysfunction
  7. women with a history of carcinoma of the breast, or women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer
  8. women with a history of uterine cancer, endometriosis, ill-defined pelvic lesions, particularly undiagnosed ovarian enlargement, undiagnosed vaginal bleeding
  9. patients with a known hypersensitivity to estradiol, transdermal skin patches, or medroxyprogesterone acetate
  10. pregnant women
  11. porphyria
  12. diabetes mellitus
  13. cholecystitis or pancreatitis
  14. history of cerebrovascular disease (stroke), epilepsy, hypertension, hypercalcemia
  15. recurrent migraine headaches
  16. malignant melanoma
  17. history of familial hyperlipoproteinemia
  18. prior hormonal therapy for the treatment of postpartum-related mood or physical symptoms within the last six months
  19. history of psychiatric illness during the two years prior to the reported onset of the current episode of depression
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Estradiol

    Experimental

    Drug: 17beta Estradiol

  • Placebo comparator
    Placebo

    Placebo comparator

    Drug: Placebos

Interventions

  • Drug17beta Estradiol

    Alora 100 microgram per day by skin patch for 6 weeks.

  • DrugPlacebos

    Placebo skin patch for 6 weeks

06

What researchers measure

Primary outcomes

  1. Beck Depression Inventory

    The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

    Time frame: 6 weeks

  2. Beck Depression Inventory

    The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

    Time frame: Baseline

07

Results

Posted Jun 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneEstradiolPlacebo
Started66
Completed65
Not completed01

Outcome measures

PrimaryBeck Depression Inventory

The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

Time frame:
6 weeks
Reported as:
Least squares mean · Units on a scale
Beck Depression Inventory
Units on a scaleEstradiolPlacebo
Beck Depression Inventory15.84 ± 3.915.3 ± 3.19
PrimaryBeck Depression Inventory

The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Beck Depression Inventory
units on a scaleEstradiolPlacebo
Beck Depression Inventory26 ± 2.6227.67 ± 3.72

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol0/6 (0%)0/6 (0%)0/6 (0%)
Placebo0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventEstradiolPlacebo
NauseaGastrointestinal disorders0/61/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EstradiolPlaceboTotal
<=18 years000
Between 18 and 65 years6612
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)EstradiolPlaceboTotal
Female6612
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EstradiolPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino5510
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EstradiolPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American224
White235
More than one race000
Unknown or Not Reported112
08

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry. 2001 May;62(5):332-6. doi: 10.4088/jcp.v62n0504. PubMed 11411813 ↗
  • Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996 Apr 6;347(9006):930-3. doi: 10.1016/s0140-6736(96)91414-2. PubMed 8598756 ↗
  • Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000 Jun;157(6):924-30. doi: 10.1176/appi.ajp.157.6.924. PubMed 10831472 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00059228
Lead sponsor
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Apr 22, 2003
Start date
Apr 17, 2003
Primary completion
Nov 15, 2016
Completion
Nov 15, 2016
Results posted
Jun 13, 2018
Last update
Jun 13, 2018

Study contacts

Peter J Schmidt, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion